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Abstract
Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only
FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology
vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeutic cancer vaccine trials. We highlight
shifts in trends for the vaccine platforms examined, common adjuvant use, target indications, antibody or treatment
combinations between past and recent trials as well as discuss the relationship between these trends and ratio
between the number of phase 3: phase 2 for different vaccine platforms. Despite the poor success rate in vaccine
approvals, registration of phase 3 trials between 2010 and 2014 were stable indicating continued investment and
efforts towards development of immunotherapeutic vaccines.
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Introduction
Significant efforts have been made towards the devel-
opment of therapies to control or eradicate cancer, a
disease that currently kills 8 million people annually
(http://globocan.iarc.fr). Between 1996 and 2014, the
FDA approved 175 drugs for the treatment of various
indications of oncology, 69 of which were approved in
the last 5 years (2009–2014) (data obtained from Cen-
treWatch). These therapies include the angiogenesis
inhibitor Avastin, the monoclonal anti-HER2/neu re-
ceptor antibody, Herceptin and the checkpoint inhibi-
tor anti-PD1. In spite of the significant progress in
other forms of cancer therapy and large number of
vaccine trials conducted, to this day only one immuno-
therapeutic cancer vaccine has received FDA approval,
the autologous dendritic-cell based immunotherapy
Provenge® (Sipuleucel-T) for the treatment of meta-
static castrate resistant hormone refractory cancer.
In this review, information on immunotherapeutic
cancer vaccine trials was examined to identify trends in
the current portfolio of investigational vaccines and
highlight the shifts in the focus in vaccine efforts over
time. To this aim, data on therapeutic cancer vaccines
was obtained from clinicaltrials.gov. registry and medtrack
(downloaded on 27th October 2014) using the search
terms “vaccine” and “cancer” or “oncology” and entries
were consolidated to remove duplicate entries. Analysis
was performed on 451 data entries of immunotherapeutic
vaccines in phase 2 trials (not including Phase 1/2) and
phase 3 trials. We evaluated the conditions targeted, vac-
cine modalities and adjuvants and combinations concur-
rently employed. Studies investigating preventative
vaccines such as Gardasil, non-cancer vaccines or im-
munotherapy with BCG were excluded. For a full analysis
of all cancer vaccines tested since 2008, inclusive of phase
1–3 trials, see Ref [13].
Review
The current landscape of vaccines in phase 2 and 3
clinical trial
Of the 451 trials examined, a substantially larger propor-
tion of phase 2 trials were registered compared to phase
3 trials (Fig. 1a). The fewer number of phase 3 trials
could be due both to a lack of progression of vaccines
from phase 2 to phase 3 (see below for further discus-
sion) as well as the consolidation of activity to multi-
centre trials collectively enrolling a larger number of
patients. Consequently, we found a higher overall num-
ber of patients enrolled in phase 3 cancer vaccine trials
(27,141 patients) versus the number enrolled in phase 2
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or phase 2/3 trials (20,042 patients), similar to what has
recently been reported [13].
Vaccine modalities under clinical investigation
Based on the information provided in the study records
(clinicaltrials.gov), company websites and linked publi-
cations the range of vaccine modalities in trial were
evaluated and included peptide-based, dendritic cell-
based, tumor cell-based, virus-based, protein-based,
anti-idiotypic antibody, immunotherapy, T cell-based,
DNA-based, bacterial-based, PBMC-based, VLP-based,
yeast-based and RNA-based vaccines, in order of preva-
lence (Table 1). Vaccines that included a cellular or im-
mune stimulatory component that could not be definitely
assigned to the other categories (including cytokine acti-
vated lymphocytes/cells) have been classified as “other
type of vaccines”. Peptide-based, dendritic cell and tumor-
based vaccines dominated in all phases hinting towards lit-
tle novelty in the types of vaccines under trial (Table 1
and Fig. 1b). However, by assigning more granular typing
Fig. 1 Summary of immunotherapeutic vaccine trials registered since 1999 to 2014. A, Total number of immunotherapeutic anti-cancer phase 2,
phase 2 & 3 and phase 3 trials in dataset collected on 27th October 2014. B, Breakdown of the vaccine categories under investigation. Values
above or below the arrow indicate the ratio of trials in Phase 3: Phase 2 for the vaccine category (# phase 3 trials/# phase 3 trials *100). C, Comparison
of vaccine categories examined in trials completed between 1999–2013 and in 2014 onwards. D, Frequency of the most used adjuvants in vaccine trials
completed between 1999–2013 and in 2014 onwards
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to these vaccine categories we reveal high diversity within
each category such as autologous versus allogenic den-
dritic cells, number of antigens (e.g. single or multi-
peptides), use of adjuvant and antigen loading systems
(peptide, protein or various virus-based), highlighting the
complex and diverse number of features incorporated
into the vaccination regime within the larger category
(Additional file 1: Table S3).
Closer examination of the 347 studies with primary
completion dates (Figure 1c, Additional file 1: Table S1)
showed that prior to 2014, the largest proportion of stud-
ies examined peptide-based vaccines whilst studies with
anticipated completion in 2014 or after are mostly den-
dritic cells based vaccines, indicating some shift in the
focus of efforts (Figure 1c). Given the only FDA ap-
proved vaccine Provenge is a dendritic-cell based im-
munotherapy it will be interesting to see what emerges
from the large number of studies investigating the
dendritic-cell based platform.
To understand if the prevalence of dendritic-cell based
vaccine efforts is due to better progression to phase 3
trials we calculated ratios for phase 3:phase 2 trials as an
estimation for the transition rate for each vaccine cat-
egory (Table 1 and Fig. 1b). Interestingly, this shift in
efforts away from peptide-based vaccines towards den-
dritic cell-based vaccines would not have been predicted
based on the transition of these vaccine categories from
Phase 2 to Phase 3. Based on ratio values, phase 3 trials
were as likely to involve peptide-based vaccines as
dendritic-cell based vaccines (Table 1 and Fig. 1b).
The same was true when the earlier (pre 2013) and
later trials (post 2013 completion) were examined sep-
arately (Additional file 1: Table S1). In another ex-
ample, despite the relatively high ratio of Phase 3:
Phase 2 trials for protein-based vaccines we saw a re-
duction in the contribution of these trial post 2013 in-
dicating that historical progression to phase 3 did not
predict for a likely hood of present-day activity of this
vaccine type. Similarly, while anti-idiotypic antibody
vaccines showed high ratio of phase 3: phase 2 trials
overall, we have evidenced a recent drop in the num-
ber of anti-idiotypic vaccines being investigated. This
is possibly due to the failure of anti-idiotype vaccines
mitumprotimut-T [5] and abagovomab [20] to im-
prove overall survival (OS) or time to progression
(TTP) in phase 3 trials despite the touted success in
earlier studies.
Overall we found that ratio of trials in Phase 3: Phase
2 did not necessarily reflect the shift in efforts within a
vaccine category.
Regarding adjuvant selection, GM-CSF and Montanide
were the most commonly included followed by IL -2,
KLH, TRICOM, QS21 and Poly-ICLC (Table 2 and
Fig. 1d). GM-CSF was often also used in combination
with Montanide or other adjuvants including QS21, TRI-
COM, and cytokines such as IL-2 and the protein carrier-
based adjuvant Keyhole limpet hemocyanin (KLH). A
phase 1 trial examining overlapping NY-ESO-1 long-
peptides has revealed that while Montanide was able to
elicit high-avidity CD4+ T cell precursors, the addition
of Poly-ICLC suppress the induction of Th2 and IL -9
producing Th9 cells. These findings indicating the po-
tential cooperative benefits for combining these com-
monly examined adjuvants to enhance the Th1
polarisation of vaccine-induced T cells in vaccine
Table 1 Categories of vaccines and immunotherapeutic studies
in Phase 2 or Phase 3 trial
Immunotherapeutic and vaccine studies under investigation
Vaccine category Phase 2 Phase 2/3 Phase 3 Totala Ratio of
Phase 3:
Phase 2b
Peptide-based 93 1 18 112 1:19
Dendritic
cell-based
74 3 11 88 1:15
Tumour
cell-based
64 3 11 78 1:17
Virus-based 46 1 5 52 1:11
Protein-based 19 1 12 32 1:63
Anti-idiotypic
antibody
18 1 9 28 1:50
Others 21 2 5 28 1:24
T cell-based 12 1 13 1:8
DNA-based 8 2 10 1:25
Bacterial-based 2 1 3 1:50
PBMC-based 2 2 NA
VLP-based 2 2 NA
Yeast-based 2 2 NA
RNA-based 1 1 NA
Grand Total 364 12 75 451 1:21
aSorted by prevalence
bratio of phase 3 trials: phase 2 trials
Table 2 Most commonly used adjuvants in therapeutic cancer trials
Number of studies including most commonly used
adjuvants/immunostimulants
Adjuvant Phase 2 Phase 2/3 Phase 3 Total
GM-CSF 92 1 16 109
Montanide 60 1 5 66
IL-2 53 3 56
KLH 16 8 24
TRICOM 10 3 13
QS21 5 1 6
Poly-ICLC 8 0 0 8
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studies [23], a strategy that may improve the efficacy of
well known adjuvants.
Considering the large number of studies examining
GM-CSF (109 of the 451 studies) there is no clear infor-
mation on the benefit of GM-CSF inclusion in the out-
come of vaccination with a number of studies finding no
benefit to the induction of immune responses or clinical
endpoints [8, 13, 17]. A more detailed discussion can be
found in the review by Kaufman et al., who report on
the inconsistency of results achieved with studies utiliz-
ing GM-CSF in immunotherapy for the treatment of
melanoma [13]. In this review only four trials included
GM-CSF controls when examining its adjuvant activity
in vaccination, with two studies observing minimal adju-
vant effect and the final two showing diminished activity
compared to IFA or BCG [13]. Overall there have been a
limited number of studies formally examining the impact
of GM-CSF as an active control in a ‘randomized’ trial
setting (NCT00324831, NCT00524277, NCT00769704)
though at least 30 trials (non-randomised, randomized
or treatment design) include GM-CSF alone as a form of
treatment indicating that there are efforts to delineate
the baseline activity of GM-CSF. This includes 8 on-
going trials (including a phase 3 trial) (Thomson Reuters
Cortellis™ database). Interestingly, despite the lack of
consistent evidence for activity, especially in phase 3,
we did not observed any decrease in the frequency of
trials with GM-CSF as an adjuvant, on the opposite
(see Fig. 1c).
Target indications
The WHO currently reports that the major cancer
killers are lung cancer, liver cancer, stomach cancer,
colorectal cancer, breast cancer and oesophageal cancer.
Melanoma was the lead indication targeted with imm-
unotherapeutic vaccines followed by prostate cancer,
lymphoma, breast cancer, non-small cell lung cancer
(NSCLC) and pancreatic cancer and a similar (though
not identical) spread between Phase 2 and Phase 3 trials.
With the exception of melanoma, the indications tar-
geted closely represent the lead indications implicated in
worldwide mortality (Fig. 2a).
A large number of melanoma trials utilized peptide-
based vaccines and prior to 2014 these trials contributed
to 11.6 % of all trials (Fig. 2a insert). The 2nd most com-
monly targeted indication, prostate cancer, has been pre-
dominantly investigated with dendritic-cell based vaccines
(17 out of 46 total registered trials) (Fig. 2 insert 1).
When comparing the top indications examined in tri-
als conducted between 1999–2013 and 2014 onwards we
observed a reduction in the proportion of vaccine trials
for Melanoma, and an increase in trials targeting Prostate
cancer, NSCLC, brain cancers, Pancreatic and Ovarian
cancer (Fig. 2b).
The selection of melanoma as primary target for thera-
peutic vaccines is most likely due to the large number of
known melanoma antigens and the natural antigenicity
of melanomas (reviewed in [13]). It has been known for
a long time that certain tumor types, among which mel-
anoma, are inherently more responsive to immune
therapy (i.e., “immunogenic”) than others. For instance,
immunotherapy is most often effective against melano-
mas (reviewed in [1]) which may regress spontaneously
[18] or in response to therapy [7] concomitant with auto-
immune symptoms. Moreover, current FDA approved “ac-
tive” immunotherapies for solid tumors [6] are limited to
only a few tumor types (e.g., melanoma, bladder, kidney,
etc.). Nevertheless, in spite of the large number of trials
into melanoma, there remains no FDA approved immuno-
therapeutic vaccines for the treatment of melanoma [19].
Registration of trials over time
The data set for phase 2 and 3 therapeutic vaccine trials
revealed a reduction in the number trials after 2011
(Fig. 3), though numbers obtained at the time of analysis
for 2015 are most likely underestimated. A cross-sectional
analysis of 955 cancer vaccination phase 1–3 trials by Lu
et al. [13] revealed a earlier decline, with a decrease in the
total number of oncology vaccine trials registered from
2008. This prior analysis also included Phase 1 trials;
hence the pattern for an earlier decline is likely due to a
decline in phase 1 studies. Interestingly, when we specific-
ally examined the 50 phase 3 trials for which a start date
was provided there was an increase in the number of trials
registered after 2010 and a steady number of trials regis-
tered between 2010–2014. Twenty nine studies did not
report start dates however we were able to segregate these
as either completed (which includes early termination or
suspension) or as ongoing or anticipated (approved but
not initiated) based on information from company web-
sites or published information (Fig. 3). These undated
values are likely to skew the results but this data suggests
that although the number of phase 2 studies may not be
increasing, and even decreasing, there is continued invest-
ment and efforts in immunotherapeutic vaccines at the
phase 3 stage (Fig. 3).
A thorough review of success rates for investigational
drugs has been recently published [9] and reported that
the percentage of oncology vaccines progressing from
phase 2 to 3 stage (39.5 %) was on par with that of
oncology product in general (28.3 %), yet still indicating
a drop off for vaccine progression between phase 2 to
phase 3. However, in the transition between phase 3 to
new drug application (NDA) or biologic license applica-
tion (BLA) although 45.2 % of all oncology products
obtained approved, only 8.3 % or (12 entities) of pre-
ventative and therapeutic vaccines sought the following
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milestone towards NDA/BLA (versus 64 % of non-
oncology vaccines), confirming that the bottle neck for
oncology vaccine progression is late in development
rather than early [3].
Combination treatments in therapeutic vaccine trials
The analysis of therapeutic trials under investigation
indicated that combination therapy is common and of
the 451 trials reviewed, 185 included a combination with
a drug (chemotherapeutic agent), mAB or procedure
(surgery, radiotherapy, hormone treatment, cell trans-
plants or standard/supportive care). Over the last two
decades, the number of vaccine-only studies were simi-
lar, however the last decade has seen an increase in the
number of trials with a combination with a mAB, drug
or procedure (Fig. 4 and Table 3).
145 trials examined vaccination in combination with a
chemotherapeutic entity and 47 of these trials specially
examined cyclophosphamide treatment. In addition, 19
trials included radiation as a prior/concurrent procedure.
Another 41 trials were combined with a monoclonal
antibody (mAB) treatment regime, which included treat-
ment with the checkpoint inhibitors anti-PD1 and anti-
CTLA-4 as well as tyrosine kinase agonists or anti-VEGF.
Details of the mAB investigated are shown in Table 3.
The rationale for the numerous studies investigating
the potential synergistic effects of combining vaccines
with conventional chemotherapeutic and radiation ther-
apies or with checkpoint inhibitors such as anti-PD1 has
been reviewed in [2, 10, 24]. Chemotherapy and radi-
ation are routinely used for the treatment of cancer, and
have been shown to promote anti-tumor immunity by
inducing immunogenic cell death as part of its intended
Fig. 2 Cancer indications under investigation in Phase II and Phase III trials. a Indications are sorted from the most evaluated (left) towards the
least (right) using a total of 451 studies. The insert shows the prevalence of studies involving peptide-based or dendritic cell based vaccine in
studies completed prior to 2014, or after 2014 (in the 347 studies where completion data was available). b Indications targeted in trials prior to
2014, and after 2014. The % value indicates the percentage contribution for the total number of vaccine trials examined
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therapeutic effect and by disrupting strategies that tu-
mors use to evade immune recognition (reviewed [4]
and [21]). CPI blockade therapies such as CTLA-4 or
PD1/PDL1 inhibitors have recently been approved for
melanoma and lung (PD1 inhibitor) cancer treatment
and have demonstrated tremendous activity as mono-
therapies. The co-administration of these monoclonal
antibodies and therapeutic vaccines may further increase
the number of responders to the therapy, in particular
for the patients that have weak natural immune re-
sponses to the tumor, or for all tumors that are weakly
immunogenic. The therapeutic potential of such
combination is currently evaluated in phase 2 and 3 with
various vaccine modalities (see Table 4). Though no
trend was observed in the number of phase 2 and 3
studies combining CPI blockade and vaccines, it is ex-
pected that this number will increase rapidly given the
accumulating clinical evidence pointing toward a prom-
ising role for checkpoint blocking antibodies in a rapidly
expanding spectrum of additional solid tumors including
renal cell cancer, ovarian cancer, bladder cancer, head and
neck cancer, and gastric cancer.
If proven successful in clinical trials, these combination
therapies could offer a multi-pronged attack against
cancers not adequately treated with a single treatment
modality.
Redefining success in immunotherapeutic vaccine trials
In the studies examined, the vast majority of Phase 2
and Phase 2 trial protocols included Efficacy or Safety
and Efficacy as an endpoint (Additional file 1: Table S2)
however an important question and issue that remains
to be solved is whether conventional endpoints such as
clinical response, time to progression, disease/progres-
sion free progression and overall survival are suitable or
ideal for assessing the efficacy of immunotherapies. Is
the expectation that an oncology vaccine should be mea-
sured with the same endpoints as conventional treat-
ments appropriate? Provenge, the only FDA approved
therapeutic vaccine achieved a 4.1-month improvement
in median survival (25.8 months in the sipuleucel-T
group vs. 21.7 months in the placebo group) but did not
show evidence for an improvement in time to disease
progression [13]. A review by [22] on the FDA approval
of anti-neoplastic agents between 2002–2012 indicated
that the majority (64 %) of regular approvals did not rely
on overall survival as the end point, but rather on pro-
gression free survival (PFS), time to progression (TTP)
or response rates. It is now being acknowledged that the
measure of immunotherapeutic activity may not fit the
linear activity timeline for more ‘immediate’ acting con-
ventional chemotherapeutic treatments (discussed in
[11, 12]). The response to immunotherapeutic activity
may be delayed, and preceded by transient increases in
tumor burden due to TILs (generally deemed to mark
progressive disease and drug failure) prior to detection
of a clinical response. In addition, immunotherapies may
exert effects against new lesions rather than primary
lesions. The recognition that immunotherapies often re-
sult in a delayed separation of survival curves also means
that alternative statistical analysis that detects events from
the point of separation should be applied to account for
this delay [12]. These observations have been considered
in the revised immune-related response criteria that ac-
counts for baseline and new lesions and changes in total




































Fig. 4 Number of trials including combinations with drugs, mAB or
procedures (surgery, radiotherapy, hormone treatment, cell transplants
or standard/supportive care) between the decades of 1994–2004 and
2005–2015 for 413 trials where start dates were available
Fig. 3 Evolution of Phase 2 and Phase 3 trial registration over time.
Using a total of 347 studies where trial start date was available the
number of phase 2 and phase 3 trial registered per year since 1999
is shown. Twenty nine phase 3 entries did not include start dates
and are sorted based on continuing (ongoing or anticipated) or
completed status
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Table 3 Combination antibody therapies under investigation
Start year for vaccine trials including mAB combinations





BEC2 mab 1 1 2
Lung 1 1 2
Racotumomab 1 1
NSCLC 1 1
Targeted Bevacizumab 1 2 1 1 5
Brain 1 1
Colorectal Cancer 1 1
Lung 1 1




Cetuximab 1 1 2
Colorectal Cancer 1 1





1 1 1 1 1 1 1 7
Breast Cancer 1 1 1 1 1 1 1 7
Rituximab 1 2 1 2 6
Leukemia 1 1























Table 3 Combination antibody therapies under investigation (Continued)
Checkpoint
inhibitor
Ipilimumab 1 3 1 1 1 7































Table 4 Vaccine trials including checkpoint inhibitor mABs
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Table 4 Vaccine trials including checkpoint inhibitor mABs (Continued)
NCT01896869
(ongoing)
A Phase 2, Multicenter Study
of FOLFIRINOX Followed by
Ipilimumab With Allogenic
GM-CSF Transfected
Pancreatic Tumor Vaccine in
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identifying appropriate the endpoints to determine suc-
cessful outcomes in cancer immunotherapy trials, may be
an important step in progressing this well-studied but up
till now, seemingly unfruitful field.
Conclusion
From this review it is apparent that over the last 15 years,
there has been substantial efforts in developing thera-
peutic vaccines encompassing various platforms. Al-
though only one vaccine, Provenge, has achieved FDA
approval, there is nevertheless continued activity in the
development of therapeutic vaccines, including Phase 3
trials. Despite the low approval rates for therapeutic vac-
cines, an appreciation of the minimal toxicity associated
with immunotherapy compared to conventional treat-
ments and the continued need to find treatments for
cancers not adequately treated with current therapies
provide the motivation to stay in the course to pursue
development of more effective immunotherapeutic vac-
cines and combination treatment regimes. Past learnings
from previous trials which have lead to the adoption of
improved endpoint criteria better suited to determining
a clinical response to immunotherapy and improved
statistical measurements capable of detecting an out-
come to immunotherapy feed the hope that ongoing ef-
forts will eventually yield improved trial outcomes and
ultimately bring benefit to the patients. In addition, the
recent approval and therapeutic success of CPI blockade
therapies have opened a new era for immunotherapies,
which may, when paired with vaccines, improve their ef-
ficacy and consequently likelihood of approval.
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